MEDIOCON INC – Lapaquistat is a synthetic small-molecule compound and active metabolite of lapaquistat acetate (TAK-475). It acts as an inhibitor of squalene synthase, an enzyme involved in the cholesterol biosynthesis pathway. Lapaquistat was investigated as a potential cholesterol-lowering compound.
Lapaquistat is a selective squalene synthase inhibitor and the active metabolite associated with TAK-475. Squalene synthase catalyzes the conversion of farnesyl pyrophosphate to squalene, a committed step in the biosynthesis of cholesterol.
By inhibiting squalene synthase, Lapaquistat has been investigated for its potential to reduce cholesterol biosynthesis and influence lipid metabolism.
Product Name: Lapaquistat
CAS Number: 189059-71-0
Molecular Formula: C₃₁H₃₉ClN₂O₈
Molecular Weight: Approximately 603.1 g/mol
Chemical Class: Squalene synthase inhibitor
Synonyms: Lapaquistat, Lapaquistatum, T-91485
PubChem CID: 9960389
UNII: PEZ79BV72X
ChEMBL ID: CHEMBL341976
DrugBank ID: DB16215
Lapaquistat inhibits squalene synthase, also known as farnesyl-diphosphate farnesyltransferase (FDFT1). This enzyme catalyzes the conversion of two molecules of farnesyl pyrophosphate into squalene.
Squalene synthase functions downstream of HMG-CoA reductase in the cholesterol biosynthetic pathway. Inhibition of this enzyme was investigated as a strategy for reducing hepatic cholesterol synthesis.
MEDIOCON INC focuses on supplying pharmaceutical and specialty chemical ingredients with emphasis on quality, consistency, technical documentation and reliable supply.
Lapaquistat quality evaluation may include identity, assay, chromatographic purity, related substances, residual solvents, water content, residue on ignition and other parameters according to the applicable product specification.
The exact analytical acceptance criteria should be confirmed against the current approved specification and batch-specific Certificate of Analysis.
Lapaquistat was investigated as a cholesterol-biosynthesis inhibitor and potential lipid-lowering compound. It has been studied in clinical and preclinical research, including investigations involving dyslipidemia and combination treatment with statins.
Development of the lapaquistat program was halted because of potential hepatic toxicity. Therefore, Lapaquistat should be described as an investigational/discontinued-development compound rather than a currently approved cholesterol-lowering medicine.
Lapaquistat is a defined synthetic small molecule with molecular formula C₃₁H₃₉ClN₂O₈ and molecular weight approximately 603.1 g/mol. PubChem identifies CAS 189059-71-0 as the primary CAS Registry Number.
Research-chemical sources describe Lapaquistat as a powder. Exact color and physical appearance should be confirmed against the actual supplier specification or batch COA rather than being assumed.
Product availability, packaging configuration, Certificate of Analysis (COA), Safety Data Sheet (SDS/MSDS), technical specifications and other documentation should be confirmed with MEDIOCON INC according to the intended application and customer requirements.
Mediocon Inc is a GMP-certified API manufacturer and bulk pharmaceutical ingredient supplier based in Aurangabad, Maharashtra, India. We specialise in supplying Lapaquistat API Manufacturer and Supplier in India (CAS 189059-71-0) and over 1,000 other Active Pharmaceutical Ingredients, excipients, herbal extracts, and nutraceutical ingredients to pharmaceutical manufacturers worldwide.
Our Lapaquistat API Manufacturer and Supplier in India is manufactured under strict quality management protocols compliant with WHO-GMP, ISO 9001:2015, and major pharmacopoeial standards (IP, BP, USP, EP). Every batch undergoes full analytical testing before release with a Certificate of Analysis.
Export Markets
Quality & Compliance